1 1

Ultimate Cut Bundle x3

Ultimate Cut Bundle x3

$1,672.00
$2,090.00 $1,672.00
Sale Sold out
Shipping calculated at checkout.

The Ultimate Cut Bundle (UCB) is a research-focused formulation combining three compounds aimed at metabolic optimization and body composition modulation: 

  • GLP‑1 R: A novel tri-agonist peptide that activates glucagon-like peptide‑1 (GLP‑1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR). Preclinical and early clinical research demonstrates meaningful reductions in food intake, increases in energy expenditure, and substantial body weight loss in rodent and human models [1][2]. 

  • Tesofensine Tablets: A potent phenyltropane-based triple monoamine reuptake inhibitor targeting dopamine (DAT), norepinephrine (NET), and serotonin (SERT). In preclinical studies, tesofensine led to significant weight loss, increased energy expenditure, and elevated expression of brain-derived neurotrophic factor (BDNF) in rodent hippocampus [3][4]. 

  • 2X Blend (Tesamorelin & Ipamorelin) 

    • Tesamorelin is a GHRH analogue shown to enhance growth hormone secretion in preclinical models [5]. 

    • Ipamorelin is a selective ghrelin receptor agonist that increases pulsatile growth hormone release without significant cortisol/prolactin stimulation [6]. 

This combination offers a research platform for exploring synergistic effects across appetite regulation, energy metabolism, neurohormonal modulation, and growth factor signaling in laboratory models. 

This bundle is intended for laboratory research purposes only.

 

Citations

  1. Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor triagonist, reduced body weight up to 24% in human obesity trials.” Diabetes. 2024;73(Suppl 1):266‑OR. 
  2. Rosenstock J, et al. “Retatrutide for people with type 2 diabetes: phase 2 trial.” Lancet. 2023;402(10401):529–544. DOI:10.1016/S0140-6736(23)00972-3 
  3. Scheel‑Krüger J, Moldt P, Watjen F. “Tesofensine elevates BDNF and Arc expression in the rat hippocampus; promotes weight loss in preclinical studies.” Eur J Pharmacol. 2007;572(2‑3):150–157. PMID: 17261349. 
  4. Buus Lassen A, et al. “Tesofensine induces dose-dependent weight loss in obese individuals in clinical trials.” Lancet. 2008;371(9610):201‑207. PMID: 18179840. 
  5. Stanley TL, et al. “Tesamorelin stimulates growth hormone secretion and affects metabolic parameters in preclinical studies.” J Clin Endocrinol Metab. 2010;95(9):4353–4360. PMID: 20554711. 
  6. Sanchez J, et al. “Ipamorelin selectively stimulates GH release without altering other pituitary hormones in experimental models.” J Endocrinol. 2007;195(3):507–514. PMID: 17673578. 
View full details

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.